Gossamer Bio
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3115 Merryfield Row Ste 120, San Diego, ...Phone Number
(858) 684-1300Website
www.gossamerbio.comRevenue
$48.5 MillionStock Symbol
GOSSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Gossamer Bio
Gossamer Bio is a clinical-stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The headquarters is located in San Diego, California.Explore more
Gossamer Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gossamer Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Gossamer Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Gossamer Bio
Earning: See what the market has to say on Gossamer Bio recently announced quarterly report
Check out if Gossamer Bio is spiking on competitors!
Click to see if Gossamer Bio had a recent Job posting/layoffs
Check if Gossamer Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Gossamer Bio launches new products
Website visits: Recent activity has been detected on your website
Gossamer Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Gossamer Bio
Find more new buyers
Compare Similar Companies to Gossamer Bio
Compare insights from companies similar to Gossamer Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Gossamer Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gossamer Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gossamer Bio.
Gossamer Bio financials insights
Gather financial insights about Gossamer Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$120M
2023
Share Placement
$212M
Gossamer Bio Tech Stack
A closer look at the technologies used by Gossamer Bio
Most Recent Scoops
Layoffs
Gossamer Bio has announced a significant reduction in force affecting approximately half of the company's workforce, alongside a sharp reduction in operating expenses as the PROSERA study winds down, as part of broader cost containment measures across the organization.
Spending/Investment, Layoffs
Project
Gossamer Bio has reported top-line results from PROSERA, its Phase III study of seralutinib in pulmonary arterial hypertension (PAH) patients, showing a placebo-adjusted improvement of 13.3 meters in six-minute walk distance at week 24 (p=0.032), which met the traditional 0.05 significance threshold but not the pre-specified 0.025 alpha threshold. All four key secondary endpoints favored seralutinib over placebo, with a stronger effect observed in the pre-specified risk-enriched subgroup.
Medical Research
Project
Gossamer Bio has reported that seralutinib significantly reduced fibrosis-parenchymal volume in the PROSERA CT-FRI substudy, representing what the company believes to be the first statistically significant reduction in fibrosis-parenchymal features demonstrated in a controlled PAH trial, with consistent effects observed across subgroups including non-CTD patients.
Pharmaceuticals
Project
Gossamer Bio has confirmed that all analyses for its NDA submission for seralutinib are on track to be completed by late August 2026, with the filing targeted for mid-September 2026, with all workstreams proceeding in parallel to the scheduled pre-NDA FDA meeting. The decision to escalate from a Type C to a Type B pre-NDA meeting was made based on the totality of clinical evidence and at the recommendation of FDA advisors, given the high unmet medical need in pulmonary arterial hypertension.
Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
Gossamer Bio News & Media
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
SAN FRANCISCO, June 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The...GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
SAN FRANCISCO, May 30, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The...GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to...Gossamer Bio Deadline: GOSS Investors with Losses in Excess of $100K Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gossamer Bio
Sign Up For FreeTo access detailed company insights
Gossamer Bio is a clinical-stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The headquarters is located in San Diego, California.... Read More
